View the Latest: Prescription Drugs
Filter
-
-
Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied
Quick TakeCertain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied or why as well as no data on prescription drugs.
-
Public Opinion on Prescription Drugs and Their Prices
Poll FindingThis chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.
-
What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid
Issue BriefThis brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare & Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.
-
Cost Concerns and Coverage Changes: A Follow-Up Survey of ACA Marketplace Enrollees
Poll FindingThis KFF survey is a follow-up survey of adults who had ACA Marketplace insurance in 2025. The survey examines the cost concerns and coverage changes that these 2025 Marketplace enrollees are experiencing following the expiration of the enhanced premium tax credits. The survey finds that half of returning enrollees say their health care costs are “a lot higher” and most expect to cut back on basic household expenses to afford coverage.
-
Eight Trends Shaping 2026 Health Care Costs
Other PostA new Peterson-KFF policy explainer lays out the health care trends shaping the 2026 policy debates, including rising premiums, spending on prescription drugs, health care price transparency and consolidation, artificial intelligence in health care, Medicaid funding cuts and other key program changes.
-
5 Key Facts About Medicaid Prescription Drugs
Issue BriefTo provide context for emerging debates about federal actions to address prescription drug costs, this issue brief highlights five key facts about Medicaid prescription drug coverage, payment, and administration.
-
Public Views on Prescription Drug Costs: Regulation, Affordability and TrumpRx
Poll FindingAmid the Trump administration's focus on lowering prescription drug costs, including its new TrumpRx website, KFF's Health Tracking Poll finds that most Americans (59%) are worried about affording prescription drugs and support more regulation of prescription drug pricing (72%). Looking ahead to the 2026 midterm elections, the Democratic party currently holds the advantage when it comes to who voters trust to address the cost of health care, including prescription drugs.
-
Poll: Public Worries About Prescription Drug Costs Reach New High; Most Across Political Parties Want Government to Do More to Regulate Prices
News ReleaseAs the Trump administration promotes its new TrumpRx website and other efforts to lower prescription drug prices, a growing majority of the public worries about being able to afford prescription drugs, and large majorities across parties want the government to do more to regulate prices, a new KFF Health Tracking Poll finds.
-
Recent Trends in Medicaid Outpatient Prescription Drugs and Spending
Issue BriefThis issue brief describes recent trends in the number of Medicaid outpatient prescriptions and the spending on those drugs and examines the implications of recent federal actions on future trends.